Optimizing the Management of High-Risk ACS Patients: Exploring Antiplatelet Approaches to Improve Patient Outcomes

Title:

Optimizing the Management of High-Risk ACS Patients: Exploring Antiplatelet Approaches to Improve Patient Outcomes

Topic: Cardiology
Relevant Terms: Myocardial Infarction, Thrombosis, Anticoagulant Therapy
Primary Audience: cardiologists; internal medicine physicians; emergency room clinicians; and other health care professionals involved in the treatment of ACS
Launch Date: 31-Jul-14
Credits: AMA PRA Category 1 Credit
Expiration Date: 30-Jul-15
Curriculum Name: Managing high-risk patients wtih ACS

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Identify high-risk ACS patients (high-risk NSTEMI, STEMI) and promptly initiate suitable risk stratification and patient management strategies
  2. Adopt and adhere to guidelines-based treatment strategies for use of appropriate antiplatelet options to reduce the risk of recurrent events
  3. Identify inefficiencies in discharge planning and patient education on the necessity of drug adherence to improve quality of care and long-term outcomes of high-risk ACS patients

    Faculty

    Dominick J. Angiolillo, MD, PhD
    Associate Professor of Medicine
    Director, Cardiovascular Research
    University of Florida College of Medicine-Jacksonville
    Division of Cardiology
    Jacksonville, FL
    Stephen D. Wiviott, MD, FACC
    Cardiovascular Division
    Brigham and Women's Hospital
    Associate Professor of Medicine
    Harvard Medical School
    Senior Investigator, TIMI Study Group
    Boston, MA
    DISCLOSURE POLICY STATEMENT
    The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
     
    All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. Disclosures will be made known to the participants prior to the activity.
     
    The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
     
    Faculty Disclosures
    The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
     
    Stephen D. Wiviott, MD, FACC:  Consultant: Daiichi-Sankyo, Eli Lilly, ICON, Johnson & Johnson, St. Jude Medical; Research: AstraZeneca, Eisai, Merck
                                                                                                 
    Dominick J. Angiolillo, MD, PhD: Advisory Board: Abbott Vascular, AstraZeneca, Bristol-Myers Squibb/Sanofi-Aventis, Eli Lilly/Daiichi-Sankyo, The Medicines Company, Merck; Data Safety Monitoring Board: Johnson & Johnson, St. Jude Medical, Sunovion; Research: AstraZeneca, Daiichi-Sankyo, Eli Lilly, Esther and King Biomedical Research, Evolva, Gilead, Johnson & Johnson, The Medicines Company; Speaker: AstraZeneca, Daiichi-Sankyo, Eli Lilly, Merck
                                                          
    Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

    Barry Watkins, PhD; Blair St. Amand; Jay Katz, CCMEP; Laurie Muldowney, MD:
    Nothing to disclose
     
    DISCLOSURE ATTESTATION
     
    DISCLAIMER
    The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
     
    CREDIT DESIGNATION
    The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.
     
    For questions regarding CME credit, the post-test, or evaluation, please email contact@rockpointe-pcme.com.
     
    ACCREDITATION STATEMENT
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    PROVIDERSHIP
    This continuing medical education activity is jointly provided by the Potomac Center for Medical Education and Rockpointe.

    COMMERCIAL SUPPORT
    This program is supported through an educational grant from Daiichi-Sankyo, Inc. and Lilly USA, LLC.
     
    HOW TO RECEIVE CREDIT
    By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 credits™. Statement of credit will be available to print from your user history page.
     
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the post-test and activity evaluation.
    • Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with a 70% or higher on the post-test to receive credit for this activity.
    All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

    COURSE VIEWING REQUIREMENTS
    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 5.0+ for Mac OSX 10.5 and above

    For video playback, install the latest version of Flash or Quicktime.
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above